Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

43.22 +0.50 (+1.17%)

Streaming Delayed Price Updated: 11:54 AM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 Next >

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast ↗

August 08, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

What to Expect from Xenon Pharmaceuticals's Earnings ↗

May 09, 2025

Via Benzinga

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Via MarketMinute

Topics Artificial Intelligence Economy

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

Via PredictStreet

Topics Economy Intellectual Property

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

Crude Oil Gains 3%; US Inflation Eases In April ↗

May 13, 2025

Via Benzinga

Topics Economy

This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 07, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.